MONTREAL, QUEBEC--(Marketwire - January 21, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) announced today that it will be hosting a conference call and webcast on Tuesday, January 22 at 9:00 am ET, to discuss the Phase III preliminary results for its proprietary prolonged-release formulation of Octreotide, C2L, in acromegaly patients.
